‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s – Global News
May 4, 2026
Health Canada has approved a second drug that can slow the progression of Alzheimer’s disease.
Donanemab, sold by American drugmaker Eli Lilly under the brand name Kisunla, received Health Canada approval on Monday, the company said in a press release.
It received approval from the U.S. Food and Drug Administration in 2024.
This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as “Leqembi,” in October 2025.
Donanemab, like lecanamab, targets amyloids — a sticky protein that develops in the brain in the early stages of Alzheimer’s disease. The buildup of amyloid plaques in the brain may lead to memory and thinking issues.
Read more: https://globalnews.ca/news/11828976/health-canada-second-drug-alzheimers/
